MedTrace Logo

An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

NCT02325219 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2020-05-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to demonstrate the superiority of CNTO 1959 (guselkumab) to placebo in the treatment of participants with moderate to severe plaque-type psoriasis (A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches).

Conditions

Interventions

DRUG

CNTO 1959 50 mg

Participants will receive subcutaneous injection of CNTO 1959 50 mg.

DRUG

CTNO 1959 100 mg

Participants will receive subcutaneous injection of CNTO 1959 100 mg.

DRUG

Placebo 50 mg

Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.

DRUG

Placebo 100 mg

Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.

Sponsors & Collaborators

  • Janssen Pharmaceutical K.K.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-19
Primary Completion
2016-03-02
Completion
2019-02-08

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02325219 on ClinicalTrials.gov